Patients
| Country | Value | Year |
|---|---|---|
| Iraq | 4.1 | 2023 |
| Israel | 6.3 | 2023 |
| Jordan | 0.9 | 2023 |
| Lebanon | 1.1 | 2023 |
| Palestine | 1.5 | 2023 |
| Qatar | 2.0 | 2023 |
| Saudi Arabia | 2.2 | 2023 |
| Syria | 1.3 | 2023 |
| UAE | 2.9 | 2023 |
| Yemen | 4.6 | 2023 |
Updated
Reviewed by Chandani Patel
Middle East Pharmacogenomic Testing for Psychiatry Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$30.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $18.2 Mn | — | — |
| 2025 (base) | $20.1 Mn | +$1.9 Mn | — |
| 2026 (forecast) | $22.2 Mn | +$2.2 Mn | +10.7% |
| 2027 (forecast) | $24.6 Mn | +$2.4 Mn | +22.5% |
| 2028 (forecast) | $27.3 Mn | +$2.6 Mn | +35.7% |
| 2029 (forecast) | $30.2 Mn | +$2.9 Mn | +50.2% |
| 2030 (forecast) | $33.4 Mn | +$3.2 Mn | +66.2% |
| 2031 (forecast) | $37.0 Mn | +$3.6 Mn | +84% |
| 2032 (forecast) | $40.9 Mn | +$4.0 Mn | +103.7% |
| 2033 (forecast) | $45.3 Mn | +$4.4 Mn | +125.5% |
| 2034 (forecast) | $50.2 Mn | +$4.8 Mn | +149.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $20.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $50.2 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 10.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, application and end user (see all) |
| Key players | Myriad Genetics, Inc., Genomind, OneOme, Tempus, Thermo Fisher Scientific Inc. (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Pharmacogenomic tests for psychiatry look at a person's genes to help doctors choose antidepressants and other mental health medicines that are likely to work.
Key segments of the pharmacogenomic Testing for Psychiatry market include test (Multi-Gene Panels and Single-Gene Tests) and application (Depression, Anxiety and ADHD).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the pharmacogenomic Testing for Psychiatry market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the pharmacogenomic Testing for Psychiatry market.
The pharmacogenomic Testing for Psychiatry market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medical devices are regulated by SFDA (Saudi Arabia)[1], EDE (UAE)[2], Ministry of Public Health (Qatar)[3] and AMAR (Israel)[4]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[5], mandatory health insurance (UAE)[6], public care and compulsory insurance (Qatar)[3] and four health funds (Israel)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Ministry of Public Health, Qatar. Checked 19 Nov 2026.
[4] Israel Ministry of Health. Checked 19 Nov 2026.
[5] Council of Health Insurance. Checked 14 Nov 2026.
[6] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing for Psychiatry products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Middle East.
What doctors and scientists are doing in Pharmacogenomic Testing for Psychiatry right now, from free public sources.
| Country | Value | Year |
|---|---|---|
| Iraq | 4.1 | 2023 |
| Israel | 6.3 | 2023 |
| Jordan | 0.9 | 2023 |
| Lebanon | 1.1 | 2023 |
| Palestine | 1.5 | 2023 |
| Qatar | 2.0 | 2023 |
| Saudi Arabia | 2.2 | 2023 |
| Syria | 1.3 | 2023 |
| UAE | 2.9 | 2023 |
| Yemen | 4.6 | 2023 |
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Middle East · 2 shared keywords
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East
Middle East
Middle East
Pharmaceuticals · Middle East
OTC & Nutraceuticals · Middle East
Pharmaceuticals · Middle East
Digital Health · Middle East
Digital Health · Middle East
Digital Health · Middle East